The Lee’s Summit, Mo., lab signed an agreement with Ithaca, N.Y.-based Cornell University to commercialize the blood test, according to the March 28 report. Instead of a biopsy, physicians can use the test to look at circulating cell-free DNA, which indicates organ damage.
The test can narrow organ damage down to tissue and cell type, which other cell-free DNA tests struggle to do. Targeting the damage helps physicians identify whether a COVID-19 patient is suffering muscle breakdown due to being bedridden or a more serious issue, like lung damage.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.